Searched for
INDIAN DRUG FACILITIES
These large-, mid- and small-cap stocks have upside potential of up to 31% in 1 year, according to analysts- FDA flags persistent data-integrity lapses, insanitary conditions at Indian drug facilities
- These mid-caps have ‘strong buy’ & ‘buy’ recos and upside potential of up to 28%, according to analysts
- With most drug candidates failing in humans, India’s draft rules bet on the wrong science in animal lab testingRecent draft rules in India threaten advancements in non-animal testing for drug development and safety. The new regulations may prioritize...04 Nov, 2026, 06.18 PM IST
- Vantara hosts EARAZA conference, puts data and technology at the heart of wildlife conservationThe four-day EARAZA Annual Conference 2026 at Anant Ambani’s Vantara in Jamnagar brought together 98 institutions from 30 countries. Vantar...03 Nov, 2026, 03.17 PM IST
- Sun Pharma ordered to halt eye drug production at Assam plant over quality lapses: ReportIndian regulators have ordered Sun Pharmaceutical Industries to stop manufacturing ophthalmic products at the Assam facility. This decision...30 Oct, 2026, 03.40 PM IST
- These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analystsWhen a market is as jittery as it is right now, poor numbers are treated harshly. A new-age company in the business of buying and selling u...28 Oct, 2026, 11.11 PM IST
- Piramal Pharma cutting China exposure to manage supply-chain resilience, says Nandini PiramalIn a strategic move to enhance risk management, Piramal Pharma has drastically cut its reliance on Chinese raw materials to under 10%. The ...28 Oct, 2026, 06.10 PM IST
- Sugar stocks: Short-term pain is real; has the long-term case broken? 7 stocks from the sugar-ethanol ecosystemThough this year's ethanol tender leaves sugar out, the long-term blending roadmap still points to rising ethanol use. The move is aimed at...26 Oct, 2026, 07.24 PM IST
- Stocks in news: Infosys, Kotak Mahindra Bank, YES Bank, Raymond, BPCL, Coforge and Senco GoldIndian equity markets have faced a decline for four consecutive sessions, with the Nifty falling significantly. Various factors, including ...26 Oct, 2026, 06.00 AM IST
- From nasal delivery to sterile injectables: Biodeal Pharmaceuticals’ expansion plansBiodeal Pharmaceuticals is set to broaden its horizons with a state-of-the-art sterile injectables plant in Himachal Pradesh. This venture ...23 Oct, 2026, 01.04 PM IST
- These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analystsThe last few weeks have made one thing clear. Oil prices, US bond yields, corporate earnings, and the state of the world – all point the sa...22 Oct, 2026, 06.33 AM IST
- Don't stunt the stent, med devices sectorThree coronary stent models from Meril Life Sciences were withdrawn from the Sri Lankan market due to performance issues. The National Medi...20 Oct, 2026, 12.36 AM IST
- These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsThe next few weeks are critical, and one should not be in a hurry to make market-related decisions. Better to be cautious – to wait and wat...16 Oct, 2026, 10.12 AM IST
- RBI to continue efforts to curb rupee volatility; external factors driving currency fall: FMFinance Minister Nirmala Sitharaman mentioned the Reserve Bank of India’s ongoing efforts to stabilize the rupee's value. She noted that th...13 Oct, 2026, 04.31 PM IST
- ET Startup Awards 2026: Deeptech wants government to step up as the first customerAt the discussion, titled ‘Building the Hard Stuff in India’, moderated by Accel partner Prashanth Prakash, founders from the space, semico...12 Oct, 2026, 10.58 AM IST
- Healthcare paradox: More access, but who pays?Scaling too fast is irrelevant. The real problem is that India still confuses more hospitals, more doctors and more medicines with better h...09 Oct, 2026, 10.00 AM IST
- CPHI Milan: Beyond generics, how Indian pharma is rewriting its global playbookAt CPHI Milan, Indian pharma players are looking beyond traditional exports, using partnerships, licensing, CDMO, and differentiated produc...08 Oct, 2026, 04.29 PM IST
- These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analystsIn the short term, be ready for volatility, and do not mistake the passing of one big event for an all-clear. In the long term, give up try...07 Oct, 2026, 10.11 PM IST
- When nothing is cheap, winners may come from any corner: 19 stocks with downside to upside potential of -28% to plus 22%Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends ...07 Oct, 2026, 05.28 PM IST
Load More
